Sanyou Biopharmaceuticals and Sinorda Biomedicine entered into a strategic cooperation agreement to advance innovative bispecific antibody drug development.
The collaboration will leverage Sanyou’s core technology platform for integrated R&D and preclinical development and “super-trillion innovative biologics discovery platform”, and Sinorda’s experience in preclinical and clinical oncology immunotherapy.
Pingsheng Hu, CEO of Sinorda, said, “Sinorda focuses on the research and development of innovative drug and industrialization of oncology immunotherapy. Our partnership with Sanyou merges our strengths, accelerating the drug development process and transforming innovative achievements into reality faster. This collaboration improves treatment choices for patients. With this shared vision, we can work together to advance innovative drug products and contribute to human health.”
Guojun Lang, CEO of Sanyou, said, “We’re truly honored to establish a strategic cooperation with Sinorda. Their strong scientific and medical expertise, robust clinical capabilities, and extensive experience in industrial collaboration perfectly align with Sanyou. Both Sanyou and Sinorda share the common goal of using biopharmaceutical technology to enhance human health. Our combined strengths and robust collaboration will open new opportunities and forge a pioneering model of cooperation between innovative drug research and development services and pharmaceutical enterprises.”
